deltatrials
Completed NA INTERVENTIONAL 1-arm NCT00546663

Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis (ISIS Pilot)

A Pilot Study to Evaluate the Tolerability of Inhaled 7% Hypertonic Saline in Infants With Cystic Fibrosis

Sponsor: CF Therapeutics Development Network Coordinating Center

Conditions Cystic Fibrosis
Interventions inhaled 7% hypertonic saline (HS)
Updated 6 times since 2017 Last updated: Aug 22, 2011 Started: Sep 30, 2007 Primary completion: May 31, 2008 Completion: Jul 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cystic Fibrosis and is currently completed. CF Therapeutics Development Network Coordinating Center leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotCompleted~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jan 2019 — Jan 2021 [monthly]

    Completed NA

  5. Jun 2018 — Jan 2019 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CF Therapeutics Development Network Coordinating Center
  • Cystic Fibrosis Foundation
Data source: CF Therapeutics Development Network Coordinating Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations